What is Nopid?
Nopid (Nopid) helps reduce cholesterol and triglycerides (fatty acids) in the blood. High levels of these types of fat in the blood are associated with an increased risk of atherosclerosis (clogged arteries).
Nopid is used to treat high cholesterol and high triglyceride levels.
Nopid may also be used for purposes not listed in this medication guide.
Nopid indications
Primary Hypercholesterolemia or Mixed Dyslipidemia
Nopid Capsules are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (total-c), Triglycerides (TG) and apolopoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia.
Severe Hypertriglyceridemia
Nopid Capsules are also indicated as adjunctive therapy to diet for treatment of adult patients with severe hypertriglyceridemia. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention.
Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of Nopid therapy on reducing this risk has not been adequately studied.
Important Limitations of Use
Nopid at a dose equivalent to 150 mg was not shown to reduce coronary heart disease morbidity and mortality in 2 large, randomized controlled trials of patients with type 2 diabetes mellitus.
How should I use Nopid?
Use Nopid capsules as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Some brands of Nopid capsules should be taken with food. Some brands may be taken with or without food. Ask your pharmacist if you should take your brand of Nopid capsules with food.
- Swallow Nopid capsules whole. Do not open, crush, dissolve, or chew before swallowing. If you cannot swallow Nopid capsules whole, tell your doctor. You may need a different medicine.
- Take Nopid capsules with a full glass of water (8 oz [240 mL]).
- If you also take a bile acid-binding resin (eg, cholestyramine), do not take it within 4 to 6 hours before or 1 hour after taking Nopid capsules. Check with your doctor if you have any questions.
- Take Nopid capsules on a regular schedule to get the most benefit from it.
- Taking Nopid capsules at the same time each day will help you remember to take it.
- Continue to take Nopid capsules even if you feel well. Do not miss any doses.
- If you miss a dose of Nopid capsules, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Nopid capsules.
Uses of Nopid in details
Use: Labeled Indications
Hypercholesterolemia or mixed dyslipidemia: Adjunctive therapy to diet for the reduction of low-density lipoprotein cholesterol (LDL-C), total cholesterol (total-C), triglycerides, and apolipoprotein B (apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in adults with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson types IIa and IIb). Use lipid-altering agents in addition to a diet restricted in saturated fat and cholesterol when response to diet and nonpharmacological interventions alone has been inadequate.
Note: While FDA-approved for hypercholesterolemia, Nopid is not a first- or second-line choice; other agents may be more suitable (ACC/AHA [Stone 2013]). In addition, use is not recommended to lower LDL-C or raise HDL-C in the absence of hypertriglyceridemia.
Hypertriglyceridemia: Adjunctive therapy to diet for treatment of adult patients with severe hypertriglyceridemia (Fredrickson types IV and V hyperlipidemia).
Off Label Uses
Primary biliary cholangitis
Data from a single-center, retrospective cohort study support the use of Nopid (in combination with ursodiol) in patients with primary biliary cholangitis (PBC) who have had an incomplete biochemical response to ursodiol monotherapy and showed significant improvement in alkaline phosphatase, a reduction in hepatic decompensation, and transplant-free survival improvement.
Nopid description
Each film-coated tablet contains Fenofibrate BP 160 mg. It also contains the following excipients: Pregelatinized starch maize, povidone, sodium lauryl sulphate, microcrystalline cellulose, crospovidone, anhydrous colloidal silica, sodium stearyl fumarate, purified water and opadry AMB OY-B-28920.
Nopid is a lipid-regulating agent. The empirical formula is C20H21O4Cl and the molecular weight is 360.83. Nopid is 2-[4-(4-chlorobenzoyl) phenoxy]-2-methyl-propanoic acid, 1-methylethyl ester.
Nopid dosage
Nopid Dosage
Generic name: Nopid 160mg
Dosage form: tablet
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
The dose of Nopid is 160 mg once daily.
Patients should be placed on an appropriate lipid-lowering diet before receiving Nopid and should continue this diet during treatment with Nopid.
Lipid levels should be monitored periodically. Therapy should be withdrawn in patients who do not have an adequate response after two months of treatment.
Nopid tablets can be given without regard to meals. Patients should be advised to swallow Nopid tablets whole. Do not crush, break, dissolve, or chew tablets.
More about Nopid (Nopid)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Espanol
- 0 Reviews - Add your own review/rating
Consumer resources
- Nopid
- Nopid (Advanced Reading)
- Other brands: Nopid, Lofibra, Lipofen, Nopid, More (1) »
Professional resources
- Nopid (FDA)
- Fenofibric Acid/Nopid (AHFS Monograph)
Related treatment guides
- Hyperlipoproteinemia
- Hyperlipoproteinemia Type IIa, Elevated LDL
- Hyperlipoproteinemia Type IIb, Elevated LDL VLDL
- Hyperlipoproteinemia Type IV, Elevated VLDL
- Hyperlipoproteinemia Type V, Elevated Chylomicrons VLDL
- More (1) »
Nopid interactions
See also:
What other drugs will affect Nopid?
Coumarin Anticoagulants
Potentiation of coumarin-type anticoagulant effect has been observed with prolongation of the PT/INR.
Caution should be exercised when Nopid is given in conjunction with coumarin anticoagulants. Nopid may potentiate the anticoagulant effect of these agents resulting in prolongation of the PT/INR. To prevent bleeding complications, frequent monitoring of PT/INR and dose adjustment of the oral anticoagulant as recommended until the PT/INR has stabilized.
Immunosuppressants
Immunosuppressant agents such as cyclosporine and tacrolimus can impair renal function and because renal excretion is the primary elimination route of fibrate drugs including Nopid capsules, there is a risk that an interaction will lead to deterioration of renal function. When immunosuppressants and other potentially nephrotoxic agents are co-administered with Nopid capsules, the lowest effective dose of Nopid capsules should be employed and renal function should be monitored.
Bile-Acid Binding Resins
Since bile-acid binding resins may bind other drugs given concurrently, patients should take Nopid at least 1 hour before or 4 to 6 hours after a bile acid binding resin to avoid impeding its absorption.
Colchicine
Cases of myopathy, including rhabdomyolysis, have been reported with fenofibrates co-administered with colchicine, and caution should be exercised when prescribing Nopid with colchicine.
Nopid side effects
See also:
What are the possible side effects of Nopid?
Clinical Trials Experience
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
Fenofibric acid is the active metabolite of Nopid. Adverse events reported by 2% or more of patients treated with Nopid and greater than placebo during double-blind, placebocontrolled trials are listed in Table 1. Adverse events led to discontinuation of treatment in 5.0% of patients treated with Nopid and in 3.0% treated with placebo. Increases in liver tests were the most frequent events, causing discontinuation of Nopid treatment in 1.6% of patients in double-blind trials.
Table 1: Adverse Events Reported by 2% or More of Patients Treated with Nopid and Greater than Placebo During the Double-Blind, Placebo-Controlled Trials
| BODY SYSTEM Adverse Event | Nopid* (N = 439) | Placebo (N = 365) |
| BODY AS A WHOLE | ||
| Abdominal Pain | 4.6% | 4.4% |
| Back Pain | 3.4% | 2.5% |
| Headache | 3.2% | 2.7% |
| DIGESTIVE | ||
| Nausea | 2.3% | 1.9% |
| Constipation | 2.1% | 1.4% |
| INVESTIGATIONS | ||
| Abnormal Liver Tests | 7.5% | 1.4% |
| Increased AST | 3.4% | 0.5% |
| Increased ALT | 3.0% | 1.6% |
| Increased Creatine Phosphokinase | 3.0% | 1.4% |
| RESPIRATORY | ||
| Respiratory Disorder | 6.2% | 5.5% |
| Rhinitis | 2.3% | 1.1% |
| * Dosage equivalent to 135 mg Nopid |
Clinical trials with Nopid did not include a placebo-control arm. However, the adverse event profile of Nopid was generally consistent with that of Nopid. The following adverse events not listed above were reported in ≥ 3% of patients taking Nopid alone:
Gastrointestinal Disorders: Diarrhea, dyspepsia
General Disorders and Administration Site Conditions: Pain
Infections and Infestations: Nasopharyngitis, sinusitis, upper respiratory tract infection
Musculoskeletal and Connective Tissue Disorders: Arthralgia, myalgia, pain in extremity
Nervous System Disorders: Dizzinesss
Postmarketing Experience
The following adverse events have been identified during postapproval use of Nopid: rhabdomyolysis, pancreatitis, renal failure, muscle spasms, acute renal failure, hepatitis, cirrhosis, anemia, asthenia, and severely depressed HDL-cholesterol levels.
Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Nopid contraindications
See also:
What is the most important information I should know about Nopid?
Hypersensitivity to Nopid or fenofibric acid or to any of the excipients of Nopid.
Severe renal impairment/insufficiency, including those receiving dialysis.
Active liver disease/dysfunction/insufficiency, including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities eg, persistent elevations in serum transaminases. Pre-existing gallbladder disease.
Photoallergy or phototoxic reaction during treatment with fibrates or ketoprofen.
Chronic or acute pancreatitis with the exception of acute pancreatitis due to severe hypertriglyceridemia.
Nopid contains lecithin soya as an excipient and therefore, Nopid should not be taken with allergic to peanut or arachis oil or soya lecithin, or related products due to the risk of hypersensitivity reactions.
Use in lactation: Nopid should not be used in nursing mothers. Because of the potential for tumorigenicity seen in animal studies, a decision should be made whether to discontinue nursing or to discontinue Nopid, taking into account the importance of Nopid to the mother. There are no data on the excretion of Nopid and/or its metabolites into breast milk.
Use in children: Safety and effectiveness in pediatric patients aged <18 years have not been established.
Active ingredient matches for Nopid:
Fenofibrate in South Korea.
List of Nopid substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Nolipax (Italy) | |
| Normalip Pro (Germany) | |
| Capsule; Oral; Fenofibrate 200 mg (Abbott) | |
| Normolip (Colombia, Dominican Republic, El Salvador, Honduras, India) | |
| NORMOLIP Capsule/ Tablet / 300mg / 10 units (Sun Pharmaceutical Industries Ltd.) | $ 1.33 |
| Normolip 300mg CAP / 10 (Sun Pharmaceutical Industries Ltd.) | $ 1.14 |
| 300 mg x 10's (Sun Pharmaceutical Industries Ltd.) | $ 1.14 |
| Capsules; Oral; Gemfibrozil 300 mg (Sun Pharmaceutical Industries Ltd.) | |
| Normolip 300 mg Capsule (Sun Pharmaceutical Industries Ltd.) | $ 0.12 |
| NORMOLIP 300MG CAPSULE 1 strip / 10 capsules each (Sun Pharmaceutical Industries Ltd.) | $ 1.48 |
| NORMOLIP cap 300 mg x 10's (Sun Pharmaceutical Industries Ltd.) | $ 1.14 |
| Nortricol (Colombia) | |
| Novalip (Tunisia) | |
| Novalip LM (Tunisia) | |
| Novastat TG | |
| Novastat TG 10+160 Tablet (Lupin Laboratories Ltd.) | $ 0.16 |
| NOVASTAT TG 160 MG/10 MG TABLET 1 strip / 10 tablets each (Lupin Laboratories Ltd.) | $ 2.07 |
| NOVASTAT TG 160 MG/20 MG TABLET 1 strip / 10 tablets each (Lupin Laboratories Ltd.) | $ 3.37 |
| NOVASTAT TG 160 MG/5 MG TABLET 1 strip / 10 tablets each (Lupin Laboratories Ltd.) | $ 1.25 |
| Novo-Fenofibrate | |
| Capsule; Oral; Fenofibrate 100 mg | |
| Novo-fenofibrate capsule 100 mg (Novopharm Limited (Canada)) | |
| Novo-Fenofibrate Micronized | |
| Capsule; Oral; Fenofibrate 200 mg | |
| Capsule; Oral; Fenofibrate 67 mg | |
| Novo-fenofibrate Micronized capsule 200 mg (Novopharm Limited (Canada)) | |
| Novo-fenofibrate Micronized capsule 67 mg (Novopharm Limited (Canada)) | |
| Novo-Fenofibrate-S | |
| Tablet; Oral; Fenofibrate 100 mg | |
| Tablet; Oral; Fenofibrate 160 mg | |
| Nu-Fenofibrate | |
| Capsule; Oral; Fenofibrate 100 mg | |
| Nu-fenofibrate capsule 100 mg (Nu Pharm Inc (Canada)) | |
| Nubrex (Philippines) | |
| Nubrex 100 mg x 100's (Sandoz) | $ 39.71 |
| Nubrex 300 mg x 30's (Sandoz) | $ 33.00 |
| Nubrex cap 100 mg 100's (Sandoz) | $ 39.71 |
| Nubrex cap 300 mg 30's (Sandoz) | $ 21.00 |
| Nuozhituo (China) | |
| Philbisrol (Vietnam) | |
| Philbisrol 250 mg x 10 Blister x 10 Tablet | |
| PHL-Fenofibrate Micro | |
| Capsule; Oral; Fenofibrate 200 mg | |
| PHL-fenofibrate Micro capsule 200 mg (Pharmel Inc (Canada)) | |
| Planitrix (Greece) | |
| PMS-Fenofibrate Micro (Canada) | |
| Capsule; Oral; Fenofibrate 200 mg | |
| PMS-fenofibrate Micro capsule 200 mg (Pharmascience Inc (Canada)) | |
| pms-Lipisans (Vietnam) | |
| pms-Lipisans 300 mg x 3 Blister x 10 Tablet | |
| Pro-Feno-Super (Canada) | |
| Tablet; Oral; Fenofibrate 100 mg | |
| Tablet; Oral; Fenofibrate 160 mg | |
| Procetofen | |
| Procetoken (Argentina) | |
See 1103 substitutes for Nopid | |
References
- DailyMed. "FENOFIBRATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "fenofibrate". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "fenofibrate". http://www.drugbank.ca/drugs/DB01039 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Nopid are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Nopid. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
